Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HST-002 is a human-derived collagen and extracellular matrix dermal filler being developed by Histogen for the treatment of facial folds and wrinkles, including nasolabial folds.[3][5][7][9][10][11] Produced via Histogen’s patented hypoxia-induced multipotent cell culture process, the product consists of naturally produced collagen and associated extracellular matrix proteins intended for injection into the dermis to restore volume and improve the appearance of facial wrinkles, positioning it as an aesthetic regenerative medicine device/biologic rather than a traditional small-molecule drug.[5][7][9][10][11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HST-002.